Comparison
Bromantane vs CJC-1295
Side-by-side of Bromantane and CJC-1295. Every row below is pulled from the compound schema and will update as our data grows. For deeper reads, follow through to each compound page.
Bromantane
Bromantane, the Russian nootropic sold as Ladasten (ADK-709), acts on dopamine to cut fatigue and anxiety without classical stimulant rebound.
CJC-1295
CJC-1295 peptide profile: GHRH analog forms (with-DAC ~7-day half-life, no-DAC Mod GRF 1-29 ~30 min), ipamorelin pairing, recovery use, dosing, side effects.
Effects at a glance
Bromantane
- •Russian RCT base (Voznesenskaya 2010, n=728) supports 50 mg daily for asthenia and fatigue over 4 weeks
- •Atypical actogenic mechanism: induces tyrosine hydroxylase rather than direct monoamine release
- •Subjective profile is anxiolytic plus mildly motivating, distinct from classical stimulants
- •Long half-life of around 11 hours supports once-daily morning dosing
- •WADA-banned since 1996; relevant for tested athletes
- •Western evidence base is thin; most published trials are Russian-language and not independently replicated
CJC-1295
- •GHRH analog that binds the GHRH receptor on pituitary somatotrophs to release endogenous GH
- •DAC variant has ~7 day half-life via albumin binding; non-DAC variant ~30 minutes
- •Teichman 2006 trial showed sustained 2 to 10 fold IGF-1 elevation at 60 to 250 mcg/kg DAC dosing
- •Anecdotal protocols pair non-DAC CJC-1295 with Ipamorelin to mimic pulsatile GH release
- •Side effects: water retention, numbness or tingling at injection site, vivid dreams, transient flushing
- •No completed phase III RCTs; research-use-only and not FDA approved
Side-by-side
| Attribute | Bromantane | CJC-1295 |
|---|---|---|
| Category | nootropic | peptide |
| Also known as | Ladasten, ADK-709, N-(4-bromophenyl)adamantan-2-amine | CJC-1295 DAC, CJC-1295 no-DAC, Mod GRF 1-29, tesamorelin analog |
| Half-life (hr) ↗ | 11 | 168 |
| Typical dose (mg) ↗ | 75 | 0.1 |
| Dosing frequency | daily, morning | weekly (DAC); 1-3x daily (non-DAC) |
| Routes | oral | subcutaneous |
| Onset (hr) | 3 | 1 |
| Peak (hr) | 168 | 3 |
| Molecular weight | 280.21 | 3367.83 |
| Molecular formula | C16H20BrN | C152H252N44O42 |
| Mechanism | Indirect dopaminergic and serotonergic actogenic activity via induction of tyrosine hydroxylase and selective increases in serotonin synthesis in hippocampus and hypothalamus. | Binds the GHRH receptor on pituitary somatotrophs, stimulating pulsatile growth-hormone release. The DAC modification extends plasma residence by tethering the peptide to serum albumin via a maleimide-cysteine bond. |
| Legal status | Approved in Russia (Ladasten); unscheduled and unapproved in US, EU, UK | Not FDA approved; research-use-only grey market; banned by WADA |
| WADA status | banned | banned |
| DEA / Rx | Not scheduled in the US | Not FDA approved; not scheduled; research-chemical status |
| Pregnancy | Not recommended | Insufficient data; not recommended |
| CAS | 87913-26-6 | 446262-90-4 |
| PubChem CID | 9576456 | 91971820 |
| Wikidata | Q4093816 | Q5012154 |
Safety profile
Bromantane
Common side effects
- mild GI upset
- headache
- skin rash
- occasional insomnia at higher doses
Contraindications
- pregnancy
- lactation
- severe hepatic impairment
- severe renal impairment
- pediatric use
Interactions
- MAOIs: theoretical additive dopaminergic and serotonergic activity(major)
- levodopa and dopamine agonists: additive dopaminergic activity(moderate)
- SSRIs and other serotonergic drugs: theoretical serotonergic additivity(moderate)
- classical stimulants: theoretical additive activity, undocumented(moderate)
CJC-1295
Common side effects
- injection-site reactions
- water retention
- numbness or tingling at injection site
- vivid dreams
- transient flushing
- head pressure or mild headache
Contraindications
- pregnancy
- active malignancy
- diabetic retinopathy (theoretical)
- history of pituitary tumor
Interactions
- Ipamorelin: synergistic GH release; commonly co-administered in anecdotal protocols(minor)
- insulin: GH-induced insulin resistance can shift glycemic control over weeks(moderate)
- corticosteroids: blunt GH-axis response; reduce expected efficacy(moderate)
Which Should You Take?
Bromantane comes out ahead for most readers on the criteria we weight: 3 catalogued goals, controlled substance, oral dosing, with a Tier-C outcome catalogued. CJC-1295 is the right call when one of the conditionals below applies.
- → If your priority is focus or working memory, pick Bromantane.
- → If your priority is fatigue resistance, pick Bromantane.
- → If your priority is post-training recovery, pick CJC-1295.
- → If your priority is growth-hormone axis, pick CJC-1295.
Edge case: If you cannot self-administer injections, Bromantane is the only oral option in this pair.
Default choice: Bromantane. Wider use case, and broader goal coverage. Reach for CJC-1295 only if your priority sits squarely in the goals it owns above.
This verdict is generated from each compound's schema (goals, legal status, evidence outcomes, dosing route). It updates automatically as our compound data evolves; the deeper read sits on each individual compound page.
Common questions
What is the difference between Bromantane and CJC-1295?
Bromantane and CJC-1295 differ in category (nootropic vs peptide), mechanism, and typical dosing. See the side-by-side table for full details.
Which has a longer half-life, Bromantane or CJC-1295?
Bromantane half-life is 11 hours; CJC-1295 half-life is 168 hours.
Can you stack Bromantane with CJC-1295?
Stack compatibility depends on mechanism overlap, legal status, and individual response. Check each compound page for specific interactions and contraindications before combining.
Go deeper